Heart Disease
Google News
Updated: 15 hours 49 min ago
Roxadustat Phase III Program Pooled Analyses Showed Positive Efficacy and No Increased Cardiovascular Risk in Patients with Anemia from Chronic Kidney Disease Versus Comparators - StreetInsider.com
Categories: Physical Diseases News
Roxadustat Phase III Program Pooled Analyses Showed Positive Efficacy and No Increased Cardiovascular Risk in Patients with Anemia from Chronic Kidney Disease Versus Comparators - Business Wire
Categories: Physical Diseases News
New Data From the Phase III DAPA-HF Trial Showed FARXIGA Reduced the Worsening of Heart Failure or Cardiovascular Death in HFrEF Patients With and Without Chronic Kidney Disease - Yahoo Finance
Categories: Physical Diseases News
New Data From the Phase III DAPA-HF Trial Showed FARXIGA Reduced the Worsening of Heart Failure or Cardiovascular Death in HFrEF Patients With and Without Chronic Kidney Disease - Business Wire
Categories: Physical Diseases News
Bruno Rodríguez: Cuba has been the victim of the most unjust, severe, prolonged system of sanctions that has even been imposed on any country - Granma English
Categories: Physical Diseases News
A Patient’s Guide to Plaque Psoriasis - U.S. News & World Report
A Patient’s Guide to Plaque Psoriasis U.S. News & World Report
Categories: Physical Diseases News
UCB Presents New Data From Rheumatology Portfolio Addressing Unmet Needs in Axial Spondyloarthritis, Psoriatic Arthritis and Lupus at 2019 ACR/ARP - Yahoo Finance
Categories: Physical Diseases News
UCB Presents New Data From Rheumatology Portfolio Addressing Unmet Needs in Axial Spondyloarthritis, Psoriatic Arthritis and Lupus at 2019 ACR/ARP - PRNewswire
Categories: Physical Diseases News
AstraZeneca (AZN) Reports Roxadustat Significantly Increased Hemoglobin Levels for Chronic Kidney Disease Patients with Anemia in Phase III OLYMPUS and ROCKIES Trials - StreetInsider.com
Categories: Physical Diseases News
AstraZeneca (AZN) Reports Roxadustat Significantly Increased Hemoglobin Levels for Chronic Kidney Disease Patients with Anemia in Phase III OLYMPUS and ROCKIES Trials - StreetInsider.com
Categories: Physical Diseases News
Aromatherapy Market is anticipated to grow at a CAGR of ~7% during the forecast period of 2019-2029 – Future Market Insights - Global Banking And Finance Review
Aromatherapy Market is anticipated to grow at a CAGR of ~7% during the forecast period of 2019-2029 – Future Market Insights Global Banking And Finance Review
Categories: Physical Diseases News
SQZ Biotech and AskBio Announce Research Collaboration to Create Immune Tolerization Products for AAV Gene Therapies - P&T Community
SQZ Biotech and AskBio Announce Research Collaboration to Create Immune Tolerization Products for AAV Gene Therapies P&T Community
Categories: Physical Diseases News
BridgeBio Pharma Reports Third Quarter 2019 Financial Results and Highlights Portfolio Progress - GlobeNewswire
BridgeBio Pharma Reports Third Quarter 2019 Financial Results and Highlights Portfolio Progress GlobeNewswire
Categories: Physical Diseases News
Cancer: What can I do to prevent it or fight it if diagnosed? - MSR News Online
Cancer: What can I do to prevent it or fight it if diagnosed? MSR News Online
Categories: Physical Diseases News
Study: Ransomware, Data Breaches at Hospitals tied to Uptick in Fatal Heart Attacks - Krebs on Security
Study: Ransomware, Data Breaches at Hospitals tied to Uptick in Fatal Heart Attacks Krebs on Security
Categories: Physical Diseases News
SQZ Biotech and AskBio Announce Research Collaboration to Create Immune Tolerization Products for AAV Gene Therapies - GlobeNewswire
SQZ Biotech and AskBio Announce Research Collaboration to Create Immune Tolerization Products for AAV Gene Therapies GlobeNewswire
Categories: Physical Diseases News
SQZ Biotech and AskBio Announce Research Collaboration to Create Immune Tolerization Products for AAV Gene Therapies - GlobeNewswire
SQZ Biotech and AskBio Announce Research Collaboration to Create Immune Tolerization Products for AAV Gene Therapies GlobeNewswire
Categories: Physical Diseases News
Mallinckrodt Announces Data Publication on the Treatment Effectiveness of Acthar® Gel (Repository Corticotropin Injection) for Resolution of Multiple Sclerosis Relapse in a U.S. Health Plan Population - Yahoo Finance
Categories: Physical Diseases News
Mallinckrodt Announces Data Publication on the Treatment Effectiveness of Acthar® Gel (Repository Corticotropin Injection) for Resolution of Multiple Sclerosis Relapse in a U.S. Health Plan Population - Yahoo Finance
Categories: Physical Diseases News
